Russian Heart Failure Journal 2013year Peculiarities antithrombotic treatment in patients with atrial fibrillation and ischemic heart disease


To access this material please log in or register

Register Authorize
2013/№3

Peculiarities antithrombotic treatment in patients with atrial fibrillation and ischemic heart disease

Gendlin G. E., Ryazantseva E. E., Melehov A. B.
State Budgetary Educational Institution of Higher Professional Education, “N.I. Pirogov Russian National Research Medical University” of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: antithrombotic therapy, coronary heart disease, treatment, atrial fibrillation

DOI: 10.18087/rhfj.2013.3.1861

Combination of IHD and AF deserve special attention when it comes to the antithrombotic treatment. Choice of the medicine will depends on disease progression, history of PCI and mode of stent . Overall risk of cardioembolic complications should also be evaluated.
  1. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population, prevalence, incidence and predictors of atrial fibrillation in the Renfrew / Paisley study. Heart. 2001;86 (5):516–521.
  2. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285 (18):2370–2375.
  3. Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation ma­nagement: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26 (22):2422–2434.
  4. Nabauer M, Gerth A, Limbourg T et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11 (4):423–434.
  5. Goette A, Bukowska A, Dobrev D et al. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J. 2009;30 (11):1411–1420.
  6. Dorian P, Guerra PG, Kerr CR et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol. 2009;2 (3):218–224.
  7. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА, 2011. Доступно на: http://scardio.ru / content / Guidelines / Rekomendations_fibrillyacia_predserdii_2012.pdf
  8. Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99 (2):295–304.
  9. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69 (6):546–554.
  10. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285 (22):2864–2870.
  11. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe? Thromb Haemost. 2010;104 (1):45–48.
  12. Keogh C, Wallace E, Dillon C et al. Validation of the CHADS2 clini­cal prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost. 2011;106 (3):528–538.
  13. Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost. 2011 Jul;9 Suppl 1:344–351.
  14. Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137 (2):263–272.
  15. Potpara TS, Polovina MM, Licina MM et al. Reliable identification of «truly low» thromboembolic risk in patients initially diagnosed with «lone» atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012;5 (2):319–326.
  16. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2‑VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. Thromb Haemost. 2012;107 (6):1172–1179.
  17. Van Staa TP, Setakis E, Di Tanna GL et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011;9 (1):39–48.
  18. Abu-Assi E, Otero-Raviña F, Allut Vidal G et al. Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. Int J Cardiol. 2013;166 (1):205–209.
  19. Olesen JB, Lip GY, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342: d124.
  20. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33 (12):1500–1510.
  21. Boriani G, Botto GL, Padeletti L et al. Improving stroke risk stratification using the CHADS2 and CHA2DS2‑VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke. 2011;42 (6):1768–1770.
  22. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14 (10):1385–413.
  23. You JJ, Singer DE, Howard PA et al. Antithrombotic Therapy for Atrial Fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141 (2 Suppl): e531S-575S.
  24. Camm AJ. The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin. Eur Heart J. 2009;30 (21):2554–2555.
  25. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority rando­mized controlled trials. Arch Intern Med. 2012;172 (5):397–402.
  26. Van de Werf F, Brueckmann M, Connolly SJ et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163 (6):931–937.
  27. Chatterjee S. Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction-Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials in Key Insights from Recent ACS Trials: Novel Therapeutics and Patient Outcomes 2012: Los Angeles.
  28. Patel MR, Mahaffey KW, Garg J et al. for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365 (10):883–891.
  29. Mischke K, Knackstedt C, Marx N. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease. Thrombosis. 2012;2012:184573.
  30. Mak KH. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2 (5).
Gendlin G.E., Ryazantseva E.E., Melehov A.B. Peculiarities antithrombotic treatment in patients with atrial fibrillation and ischemic heart disease. Russian Heart Failure Journal. 2013;14 (3):135-140

To access this material please log in or register

Register Authorize
Ru En